ThermiVa for Stress Incontinence

One out of every three women in the United States has stress incontinence. Did you know that women are twice as likely as men to suffer from involuntary leakage?

Stress incontinence can cause unintentional leaking of urine during such activities as coughing, laughing, sneezing, or exercising.  It’s important to remember that the term “stress” is used in a strictly physical sense when describing stress incontinence. It refers to excessive pressure on the bladder and not emotional stress.

Women who have received radiation therapy to the pelvic area due to cancer of the cervix or uterus can experience this problem.  Also affected are breast cancer patients who receive chemotherapy treatment and/or hormone therapy.  Past surgeries in the pelvic region also can contribute to the development of stress incontinence.

For some women, this incontinence is an occasional problem, but for others it is an everyday occurrence that causes discomfort and impacts their quality of life. Stress incontinence may cause embarrassment and distress and limit work and social life.

Treatment for stress incontinence may include performing pelvic floor muscles exercises known as Kegel exercises.  Surgery is another option; however, unfortunately, surgery has its risks and side effects.

A new treatment has emerged called ThermiVa. Using a temperature-controlled radio-frequency system, the ThermiVA wand transfers heat to areas that need tightening or restoration. The procedure heats tissue, which stimulates fibroblasts to make collagen. What does this mean? This process tightens and strengthens the urethra and pelvic floor muscles that help control urination. Treatment consists of three visits one month apart.

With this ThermiVa treatment, the majority of women see a marked decrease in their incontinence, with some experiencing a complete resolution of the issue. I am proud to bring this technology to the area! For more information or to make your appointment today, please call 479-648-1800.

No Comments Yet.

Leave a comment